232 research outputs found
Liquid biopsy in gastrointestinal stromal tumors: a novel approach
The role of molecular analysis in the management of gastrointestinal stromal tumors (GIST) remains indisputable. To date, tumor tissue extracted from specimens obtained by surgical or biopsy procedures has been the only source of the tumor DNA required for the molecular and genomic assessment of cancer. However, tumor tissue sampling has several clinical limitations: for example, the invasiveness of these procedures precludes repeated sampling. Thus, it is possible to obtain only a static molecular picture of the disease, a picture that lacks the inter- and intra-metastatic molecular heterogeneity that characterizes most GIST. In contrast, circulating tumor DNA obtained from a patient's bloodstream, known as liquid biopsy, can theoretically overcome the limitations of tissue biopsies and provide the same molecular and genomic information. GIST are recognized as a paradigm of molecular biology among solid tumors. Although few but promising data on liquid biopsy in GIST have been accumulated to date, these tumors may provide the optimal field for application of this challenging approac
Neoadjuvant Treatment in Rectal Cancer: Actual Status
Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3-4, N0, M0) and III (cT1-4, N+, M0) according to International Union Against Cancer (IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections), shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and discrepancies in the treatment of locally advanced rectal adenocarcinomas
Specialisation in Palliative Medicine for Physicians in Europe 2014 - A supplement of the EAPC Atlas of Palliative Care in Europe
This booklet describes the existing programmes on specialisation in palliative medicine within the WHO European region
Comparative analysis of specialization in palliative medicine processes within the World Health Organization European region
Abstract, Context
Palliative medicine (PM), still in the development phase, is a new, growing specialty aimed at caring for both oncology and non-oncology patients. There is still confusion about the training offered in the various European PM certification programs.
Objectives
To provide a detailed, comparative update and analysis of the PM certification process in Europe, including the different training approaches and their main features.
Methods
Experts from each country completed an online survey addressing historical background, program name, training requirements, length of time in training, characteristic and content, official certifying institution, effectiveness of accreditation, and 2013 workforce capacity. We prepared a comparative analysis of the data provided.
Results
In 2014, 18 of 53 European countries had official programs on specialization in PM (POSPM): Czech Republic, Denmark, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Italy, Latvia, Malta, Norway, Poland, Portugal, Romania, Slovakia, and the U.K. Ten of these programs were begun in the last five years. The PM is recognized as a “specialty,” “subspecialty,” or “special area of competence,” with no substantial differences between the last two designations. The certification contains the term “palliative medicine” in most countries. Clinical training varies, with one to two years being the most frequent duration. There is a clear trend toward establishing the POSPM as a mandatory condition for obtaining a clinical PM position in countries' respective health systems.
Conclusion
PM is growing as a specialization field in Europe. Processes leading to certification are generally long and require substantial clinical training. The POSPM education plans are heterogeneous. The European Association for Palliative Care should commit to establishing common learning standards, leading to additional European-based recognition of expertise in PM
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. They are characterized by gain of function mutations in KIT or PDGFRA tyrosine kinase receptors, with their consequent constitutive activation. The gold standard therapy is imatinib that offers a good and stable response for approximately 18-36 months. However, resistance is very common and it is vital to identify new biomarkers. Up until now, there have been two main approaches with focus to characterize novel targets. On the one hand, the focus is on the tumor genome, as the final clinical outcome depends mainly from the cancer specific mutations/alterations patterns. However, the germline DNA is important as well, and it is inconceivable to think the patients response to the drug is not related to it. Therefore the aim of this review is to outline the state of the art of the personalized medicine in GIST taking into account both the tumor DNA (somatic) and the patient DNA (germline)
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations
The employment of anti-epidermal growth factor receptor (EGFR) antibodies
represents a backbone of the therapeutic options for the treatment of metastatic
colorectal cancer (mCRC). However, this therapy is poorly effective or ineffective in
unselected patients. Mutations in KRAS, BRAF and PIK3CA genes have recently
emerged as the best predictive factors of low/absent response to EGFR-targeted
therapy. Due to the need for efficacious treatment options for mCRC patients bearing
these mutations, in this short report we examined the antitumoral activity of the
protease inhibitor gabexate mesilate, alone and in combination with the anti-EGFR
monoclonal antibody cetuximab, in a panel of human CRC cell lines harbouring a
different expression pattern of wild-type/mutated KRAS, BRAF and PIK3CA genes.
Results obtained showed that gabexate mesilate significantly inhibited the growth,
invasive potential and tumour-induced angiogenesis in all the CRC cells employed in
this study (including those ones harbouring dual KRAS/PIK3CA or BRAF/PIK3CA
mutation), while cetuximab affected these parameters only in CRC cells with KRAS,
BRAF and PIK3CA wild-type. Notably, the antitumoral efficacy of gabexate mesilate
and cetuximab in combination was found to be not superior than that observed with
gabexate mesilate as single agent. Overall, these preliminary findings suggest that
gabexate mesilate could represent a promising therapeutic option for mCRC patients,
particularly for those harbouring KRAS, BRAF and PIK3CA mutations, either as monotherapy
or in addition to standard chemotherapy regimens. Further studies to better
elucidate gabexate mesilate mechanism of action in CRC cells are therefore
warranted
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
The search for systemic therapies for hepatocellular carcinoma has been characterized by difficulties and failures. Despite recent progresses, many issues are still to be settled. In particular, the development of drugs inhibiting different neoplastic pathways remains a priority for patients intolerant or resistant to antiangiogenic drugs. This task may be daunting, as previous failures extensively demonstrated. We aimed to identify the future perspective of postsorafenib trials analyzing the strengths and the critical points of past and currently undergoing studies, in the light of the most recent evidences in the field. We identified various points (including stratification, biomarkers, end points, radiologic criteria of response, treatment beyond radiologic progression) that should be considered by future trials to reduce the risks of failure
SDHC methylation in gastrointestinal stromal tumors (GIST): a case report
Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically heterogeneous disease. In addition to KIT or PDGFRA mutated GIST, mutational inactivation of succinate dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type subgroup, referred to as SDH deficient (dSDH). Even though most dSDH GIST harbor mutations in SDHx subunit genes, some are SDHx wild type. Epigenetic regulation by DNA methylation of CpG islands recently has been found to be an alternative mechanism underlying the lack of SDH complex in GIST
Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor
Gastrointestinal stromal tumors (GISTs) are known to be poorly responsive to conventional chemotherapy and historically considered resistant to radiotherapy. In the past the mainstay of GIST treatment was surgery, but the introduction of tyrosine kinase inhibitors (TKIs) imatinib and sunitinib marked the beginning of a new era in the treatment of GIST patients. To date, radiotherapy for GIST has not been administered in clinical practice except for limited palliative settings and there are no clear data on the administration of radiotherapy, alone or in combination with TKIs, with a purely cytoreductive intent. We describe the clinical case of a 48-year-old woman with metastatic GIST treated with external radiotherapy in a critical supraclavicular tumor localization progressively increasing in size with several symptoms and not responsive to systemic TKI therapies. We obtained an initial shrinkage of the mass and subsequent stabilization with an immediate and clear clinical benefit. Although the historical medical literature considered GISTs resistant to radiation therapy, our clinical case suggests this treatment may be appropriate in selected patients
- …